Diagnosis and treatment of primary immunodeficiency disease: The role of the otolaryngologist

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 32, Issue 4, 2011, Pages 329-337

  Wasserman, Richard L ^a   Manning, Scott C ^b  

^a DallasAllergyImmunology   (United States)

^b W 7729 Otolaryngology ENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ANAPHYLAXIS; ASEPTIC MENINGITIS; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG COST; DRUG INDUCED HEADACHE; DRUG SAFETY; EAR INFECTION; ERYTHEMA MULTIFORME; FLUSHING; HEMOLYSIS; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NOSE INFECTION; OTOLARYNGOLOGIST; PATIENT MONITORING; PHARYNGITIS; PHYSICIAN; PRIORITY JOURNAL; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; THORAX DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME; VASCULAR ACCESS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; OTOLARYNGOLOGY; OTORHINOLARYNGOLOGIC DISEASES;

EID: 79959897752     PISSN: 01960709     EISSN: 1532818X     Source Type: Journal    
DOI: 10.1016/j.amjoto.2010.05.001     Document Type: Review

References (64)

1. Geha RS, Notarangelo LD, Casanova JL, et al, for the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007;120:776-94.
2. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007;27:497-502. (Pubitemid 47319256)
3. Joshi AY, Iyer VK, Hagan JB, et al. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc 2009;84:16-22.
4. Immune Deficiency Foundation. Diagnostic and clinical care guidelines for primary immunodeficiency diseases. Available at: http://www.primaryimmune.org/ publications/book-diag/IDF-Diagnostic-and- Clinical-Care-Guidelines-Final.pdf 2006. Accessed October 6, 2008.
5. Yarmohammadi H, Estrella L, Doucette J, et al. Recognizing primary immune deficiency in clinical practice. Clin Vaccine Immunol 2006;13:329-32.
6. Cunningham-Rundles C, Knight AK. Common variable immune deficiency: reviews, continued puzzles, and a new registry. Immunol Res 2007;38:78-86. (Pubitemid 47574933)
7. Stiehm ER, Ochs HD, Winkelstein JA, editors. Immunologic disorders in infants and children. 5th ed. Philadelphia (PA): Elsevier Saunders; 2004.
8. Manning SC, Wasserman RL, Leach J, et al. Chronic sinusitis as a manifestation of primary immunodeficiency in adults. Am J Rhinol 1994;8:29-36.
9. Bonilla FA, Bernstein IL, Khan DA, et al, and the American Academy of Allergy, Asthma, and Immunology; the American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94(Suppl 1):S1-63.
10. Immune Deficiency Foundation. Primary immune deficiency diseases in America: 2002. The second national survey of patients. Available at: http://www.info4pi.org/patienttopatient/pdf/10-warnings-poster-eng.pdf 2008. Accessed October 7, 2008.
11. Cooney TR, Huissoon AP, Powell RJ, et al. Investigation for immunodeficiency in patients with recurrent ENT infections. Clin Otolaryngol Allied Sci 2001;26:184-8. (Pubitemid 34204391)
12. Stiehm ER. The four most common pediatric immunodeficiencies. J Immunotoxicol 2008;5:227-34. (Pubitemid 351882417)
13. Wood P, Stanworth S, Burton J, et al. UK Primary Immunodeficiency Network. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007;149:410-23.
14. Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007;27:308-16. (Pubitemid 46790816)
15. Oksenhendler E, Gerard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008;46:1547-54. (Pubitemid 351706736)
16. Bondioni MP, Duse M, Plebani A, et al. Pulmonary and sinusal changes in 45 patients with primary immunodeficiencies: computed tomography evaluation. J Comput Assist Tomogr 2007;31:620-8. (Pubitemid 47457682)
17. Urschel S, Kayikci L, Wintergerst U, et al. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr 2009;154:888-94.
18. Shapiro GG, Virant FS, Furukawa CT, et al. Immunologic defects in patients with refractory sinusitis. Pediatrics 1991;87:311-6.
19. Chee L, Graham SM, Carothers DG, et al. Immune dysfunction in refractory sinusitis in a tertiary care setting. Laryngoscope 2001;111:233-5. (Pubitemid 32142829)
20. Baraniuk JN, Maibach H. Pathophysiological classification of chronic rhinosinusitis. Respir Res 2005;6:149.
21. Vanlerberghe L, Joniau S, Jorissen M. The prevalence of humoral immunodeficiency in refractory rhinosinusitis: a retrospective analysis. B-ENT 2006;2:161-6. (Pubitemid 47521698)
22. Mynatt RG, Do J, Janney C, et al. Squamous metaplasia and chronic rhinosinusitis: a clinicopathological study. Am J Rhinol 2008;22:602-5.
23. Manning SC. Surgical management of sinus disease in children. Ann Otolaryngol Rhinol Laryngol Suppl 1992;155:42-5.
24. Eades-Perner AM, Gathmann B, Knerr V, et al, and the ESID Registry Working Party. The European Internet-based patient and research database for primary immunodeficiencies: results 2004-06. Clin Exp Immunol 2007;147:306-12. (Pubitemid 46096009)
25. Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005;58:546-7. (Pubitemid 40646879)
26. Verbsky JW, Grossman WJ. Cellular and genetic basis of primary immune deficiencies. Pediatr Clin North Am 2006;53:649-84. (Pubitemid 44092901)
27. World Health Organization. Primary immunodeficiency diseases. Report of a WHO scientific group. Clin Exp Immunol 1997 (Suppl 1):1-28.
28. Ballow M. Primary immunodeficiency disorders. J Allergy Clin Immunol 2002;109:581-91.
29. Shackelford PG, Granoff DM, Madassery JV, et al. Clinical and immunologic characteristics of healthy children with subnormal serum concentrations of IgG2. Pediatr Res 1990;27:16-21. (Pubitemid 20023165)
30. Herrod HG. Clinical significance of IgG subclasses. Curr Opin Pediatr 1993;5:696-9. (Pubitemid 24032950)
31. Bonilla FA, Geha RS. Primary immunodeficiency diseases. J Allergy Clin Immunol 2003;111:S571-S581.
32. Rosenzweig SD, Holland SM. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 2004;113:620-6. (Pubitemid 38530414)
33. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008;28:413-37. (Pubitemid 351522414)
34. Orange JD, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525-S553.
35. Bonagura VR, Marchlewski R, Cox A, et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122:210-2. (Pubitemid 351899076)
36. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-8.
37. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980;93:55-6. (Pubitemid 10072004)
38. ImmuneDeficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. Available at: http://www.primaryimmune.org/publications/surveys/Treatment- Experiences-and-Preferences-(2003).pdf 2003. Accessed October 20, 2008.
39. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006;26:177-85. (Pubitemid 43869918)
40. Ochs HD, Gupta S, Kiessling P, et al, and the Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265-73. (Pubitemid 43901655)
41. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991;338:162-6.
42. Gardulf A, Björvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995;21:917-27.
43. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94-100. (Pubitemid 30314313)
44. United States Food and Drug Administration. Product approval information - licensing action. Available at: http://www.fda.gov/CBER/approvltr/ igsczlb010906L.htm 2006. Accessed October 9, 2008.
45. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004;112:1-7. (Pubitemid 38781052)
46. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998;79:48-51. (Pubitemid 28331253)
47. Dollery CM, Sullivan ID, Bauraind O, et al. Thrombosis and embolism in long-term central venous access for parenteral nutrition. Lancet 1994;344:1043-5. (Pubitemid 24310034)
48. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-62. (Pubitemid 23302151)
49. Davé S, Hagan J. Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration. Ann Allergy Asthma Immunol 2007;99:567-70. (Pubitemid 350308758)
50. Orbach H, Katz U, Sherer Y, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84. (Pubitemid 43041668)
51. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2004;83:661-5. (Pubitemid 39317492)
52. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007;122:156-62. (Pubitemid 46073896)
53. Eijkhout HW, van den Broek PJ, van der Meer JW. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003;61:213-7. (Pubitemid 39089400)
54. Shapiro R. Rapid push of immune globulin replacement therapy is preferred to pump in patients with primary immune deficiency: a retrospective study in one clinic. Poster presented at American Academy of Allergy, Asthma, and Immunology; March 13-17, 2009; Washington, DC; 2009.
55. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365-9.
56. Björkander J, Bake B, Hanson LA. Primary hypogammaglobulinaemia: impaired lung function and body growth with delayed diagnosis and inadequate treatment. Eur J Respir Dis 1984;65:529-36. (Pubitemid 14038813)
57. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987;1:1075-7. (Pubitemid 17061340)
58. Plebani A, Soresina A, Rondelli R, et al, and the Italian Pediatric Group for XLA-AIEOP. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002;104:221-30.
59. Johnston SL, Hill SJ, Lock RJ, et al. Echocardiographic abnormalities in primary antibody deficiency. Postgrad Med J 2004;80:214-8. (Pubitemid 38561401)
60. Boyle ML, Scalchunes C. Impact of intravenous immunoglobulin (IVIG) treatment among patients with primary immunodeficiency disease. Pharm Policy Law 2008;10:133-46.
61. Gardulf A, Björvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993;92:200-4. (Pubitemid 23151026)
62. Gardulf A, Nicolay U, Asensio O, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114:936-42. (Pubitemid 39330270)
63. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008;28:370-8.
64. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006;26:65-72. (Pubitemid 43112626)